<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with cinacalcet and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine by decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Reduction of the plasma concentrations of the vortioxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the viortioxetine during the treatment with the paroxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
<ATC code="C01BA51" />
<ATC code="C01BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring andpossible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped</COMMENT>
</INTERACTION>
</INTERACTIONS>
